GlassScriptPhysician profile
Abby Hayes
NPI 1881125680
$2,638.79
in general payments reported to CMS, 2019-2025
31 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $216 · 2023: $688 · 2024: $1,099 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $572.04 | 2022-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $411.16 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $246.31 | 2023-2025 | |
| Lundbeck LLC | $204.15 | 2023-2024 | Vyepti |
| Amgen INC. | $117.91 | 2022-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $110.51 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $105.55 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $100.55 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $100.29 | 2023-2025 | |
| Dexcom, INC. | $70.43 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.58 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $59.03 | 2023-2024 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $47.98 | 2022-2023 | Trintellix |
| Aimmune Therapeutics, INC. | $46.23 | 2024-2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $44.85 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $40.05 | 2024 | Keveyis |
| Teva Pharmaceuticals USA, INC. | $33.93 | 2024 | Uzedy |
| Nestle Healthcare Nutrition INC. | $31.30 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.51 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.84 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $21.75 | 2024 | Inspire |
| Averitas Pharma INC. | $21.63 | 2024 | Qutenza |
| Sumitomo Pharma America, INC. | $17.74 | 2025 | Gemtesa |
| Digestive Care, INC. | $17.21 | 2024 | Pertzye |
| Insulet Corporation | $16.43 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.99 | 2024 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $15.47 | 2024 | Strensiq |
| Merck Sharp & Dohme LLC | $14.72 | 2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $14.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.32 | 2023 | |
| Shield Therapeutics INC | $13.06 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.